Role of Poly(ADP-Ribose) Polymerase Activation in Diabetic Neuropathy

Diabetes

Volumn 53, Issue 3, 2004, Pages 711-720

  Obrosova, Irina G ^a   Li, Fei ^a   Abatan, Omorodola I ^a   Forsell, Mark A ^b   Komjáti, Katalin ^c   Pacher, Pal ^c,d   Szabó, Csaba ^c   Stevens, Martin J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Veritas Laboratories   (United States)

^c INOTEK CORPORATION   (United States)

^d NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ISOQUINOLINEDIOL; 3 AMINOBENZAMIDE; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; POLY(ADENOSINE DIPHOSPHATE RIBOSE); UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIABETIC NEUROPATHY; DNA DAMAGE; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; MALE; MOTOR NERVE; NERVE CONDUCTION; NEUROPATHY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; SCHWANN CELL; SCIATIC NERVE; SENSORY NERVE; WILD TYPE;

ANIMALS; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; ENZYME ACTIVATION; GENE DELETION; MALE; MICE; NEURAL CONDUCTION; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, WISTAR; REFERENCE VALUES; REGIONAL BLOOD FLOW; SCIATIC NERVE;

EID: 1442325591     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.3.711     Document Type: Article

References (50)

1. Boulton AJ: Treatments for diabetic neuropathy. Curr Diab Rep 1:127-132, 2001
2. Nakamura J, Kato K, Hamada Y, Nakayama M, Chaya S, Nakashima E, Naruse K, Kasuya Y, Mizubayashi R, Miwa K, Yasuda Y, Kamiya H, Ienaga K, Sakakibara F, Koh N, Hotta N: A protein kinase C-β-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 48:2090-2095, 1998
3. Yagihashi S, Yamagishi SI, Wada R, Baba M, Hohman TC, Yabe-Nishimura C, Kokai Y: Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitors. Brain 124:2448-2458, 2001
4. Obrosova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ: An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 16:123-125, 2002
5. Song Z, Fu DTW, Chan Y-S, Leung S, Chung SSM, Chung SK: Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress. Mol Cell Neurosci 23:638-647, 2003
6. Dickinson PJ, Carrington AL, Frost GS, Boulton AJ: Neurovascular disease, antioxidants and glycation in diabetes. Diabetes Metab Res Rev 18:260-272, 2002
7. Thornalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 50:37-57, 2002
8. Cameron NE, Cotter MA, Jack AM, Basso MD, Hohman TC: Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats. Diabetologia 42:1120-1130, 1999
9. El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB: High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 44:3135-3143, 2003
10. Stern DM, Yan SD, Yan SF, Schmidt AM: Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 1:1-15, 2002
11. Abiko T, Abiko A, Clermont AC, Shoelson B, Horio N, Takahashi J, Adamis AP, King GL, Bursell SE: Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase C activation. Diabetes 52:829-837, 2003
12. Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA: Effects of DL-α-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 49:1006-1105, 2000
13. Obrosova IG, Van Huysen C, Fathallah L, Cao X, Stevens MJ, Greene DA: Evaluation of alpha(1)-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 14:1548-1558, 2000
14. Obrosova IG, Fathallah L, Stevens MJ: Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp Neurol 172:211-219, 2001
15. Low PA, Nickander KK, Tritschler HJ: The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 46 (Suppl. 2):S38-S42, 1997
16. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA: Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 50:1927-1937, 2001
17. Coppey LJ, Gellett JS, Davidson EP, Yorek MA: Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation. Free Radic Res 37:33-40, 2003
18. Hounsom L, Corder R, Patel J, Tomlinson DR: Oxidative stress participates in the breakdown of neuronal phenotype in experimental diabetic neuropathy. Diabetologia 44:424-428, 2001
19. Purves T, Middlemas A, Agthong S, Jude EB, Boulton AJ, Fernyhough P, Tomlinson DR: A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J 15:2508-2514, 2001
20. Sagara M, Satoh J, Wada R, Yagihashi S, Takahashi K, Fukuzawa M, Muto G, Muto Y, Toyota T: Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine. Diabetologia 39:263-269, 1996
21. Hoeldtke RD, Bryner KD, McNeill DR, Hobbs GR, Riggs JE, Warehime SS, Christie I, Ganser G, Van Dyke K: Nitrosative stress, uric acid, and peripheral nerve function in early type 1 diabetes. Diabetes 51:2817-2825, 2002
22. Garcia Soriano F, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KG, Salzman AL, Southan GJ, Szabo C: Diabetic endothelial dysfunction: the role of poly (ADP-ribose) polymerase activation. Nat Med 7:108-113, 2001
23. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C: The role of poly (ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51:514-521, 2002
24. Virag L, Szabo C: The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54:375-429, 2002
25. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, Poirier GG, Dawson TM, Dawson VL: Mediation of poly (ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297:259-263, 2002
26. Berciano MT, Fernandez R, Pena E, Calle E, Villagra NT, Lafarga M: Necrosis of Schwann cells during tellurium-induced primary demyelination: DNA fragmentation, reorganization of splicing machinery, and formation of intranuclear rods of actin. J Neuropathol Exp Neurol 58:1234-1243, 1999
27. Soldatenkov VA, Chasovskikh S, Potaman VN, Trofimova I, Smulson ME, Dritschilo A: Transcriptional repression by binding of poly (ADP-ribose) polymerase to promoter sequences. J Biol Chem 277:665-670, 2002
28. Ha HC, Hester LD, Snyder SH: Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc Natl Acad Sci U S A 99:3270-3275, 2002
29. Minchenko AG, Stevens MJ, White L, Abatan OI, Komjati K, Pacher P, Szabo C, Obrosova IG: Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly (ADP-ribose) polymerase activation. FASEB J 17:1514-1516, 2003
30. Schmeichel AM, Schmelzer JD, Low PA: Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 52:165-171, 2003
31. Mizisin AP, Steinhardt RC, O'Brien JS, Calcutt NA: TX14(A), a prosaposin-derived peptide, reverses established nerve disorders in streptozotocin-diabetic rats and prevents them in galactose-fed rats. J Neuropathol Exp Neurol 60:953-960, 2001
32. Wang ZQ, Auer B, Stingl L, Berghammer H, Haidacher D, Schweiger M, Wagner EF: Mice lacking ADPRT and poly (ADP-ribosyl) ation develop normally but are susceptible to skin disease. Genes Dev 9:509-520, 1995
33. Obrosova IG, Fathallah L, Lang HJ, Greene DA: Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: a prevention study. Diabetologia 42:1187-1194, 1999
34. Tuck RR, Schmelzer JD, Low PA: Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 107:935-950, 1984
35. Symons NA, Danielsen N, Harvey AR: Migration of cells into and out of peripheral nerve isografts in the peripheral and central nervous systems of the adult mouse. Eur J Neurosci 14:522-532, 2001
36. Nasu K, Whyte A, Green SJ, Evans PC, Kilshaw PJ: Alpha-galactosyl-mediated activation of porcine endothelial cells: studies on CD31 and VE-cadherin in adhesion and signaling. Transplantation 68:861-867, 1999
37. Obrosova I, Seigel G, Frank R, Abatan O, Pacher P, Komjati K, Stevens M, Szabo C: Early diabetes-induced changes in the retina: comparison of STZ-induced models in rat and mouse (Abstract). Diabetes 52 (Suppl. 1):A202, 2003
38. Szabo C, Zanchi A, Komjati K, Pacher P, Krolewski AS, Quist WC, LoGerfo FW, Horton ES, Veves A: Poly (ADP-ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 106:2680-2686, 2002
39. Stevens MJ, Lattimer SA, Feldman EL, Helton ED, Millington DS, Sima AA, Greene DA: Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na, K-ATPase activity, and motor conduction velocity in the streptozotocin-diabetic rats. Metabolism 45:865-872, 1996
40. Cameron NE, Gibson TM, Cotter MA: Effects of poly(ADP-ribose) polymerase inhibition in large and small nerve fibre function in experimental diabetes (Abstract). Diabetologia 46 (Suppl. 2):A315, 2003
41. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C: Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly-(ADP-ribose) polymerase. Circ Res 89:684-691, 2001
42. Cameron NE, Eaton SE, Cotter MA, Tesfaye S: Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44:1973-1988, 2001
43. Obrosova I, Cao X, Greene DA, Stevens MJ: Diabetes-induced changes in lens antioxidant status, glucose utilization and energy metabolism: effect of DL-alpha-lipoic acid. Diabetologia 41:1442-1450, 1998
44. Obrosova IG, Fathallah L: Evaluation of an aldose reductase inhibitor on lens metabolism, ATPases and antioxidative defense in streptozotocin-diabetic rats: an intervention study. Diabetologia 43:1048-1055, 2000
45. Calcutt NA, Allendoerfer KL, Mizisin AP, Middlemas A, Freshwater JD, Burgers M, Ranciato R, Delcroix JD, Taylor FR, Shapiro R, Strauch K, Dudek H, Engber TM, Galdes A, Rubin LL, Tomlinson DR: Therapeutic efficacy of sonic hedgehog protein in experimental diabetic neuropathy. J Clin Invest 111:507-514, 2003
46. Obrosova IG, Li F, Abatan OI, Pacher P, Souhan GJ, Szabo C, Stevens MJ: Evaluation of orally active poly(ADP-ribose)polymerase inhibitor in the model of early diabetic neuropathy (Abstract). Diabetologia 46 (Suppl. 2):A71, 2003
47. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M: Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112:1049-1057, 2003
48. Fernyhough P, Gallagher A, Averill SA, Priestley JV, Hounsom L, Patel J, Tomlinson DR: Aberrant neurofilament phosphorylation in sensory neurons of rats with diabetic neuropathy. Diabetes 48:881-889, 1999
49. Stevens EJ, Tomlinson DR: Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes. Br J Pharmacol 115:373-379, 1995
50. Pop-Busui R, Marinescu V, Van Huysen C, Li F, Sullivan K, Greene DA, Larkin D, Stevens MJ: Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. Diabetes 51:2619-2628, 2002